pentobarbital will minimize the extent or outcome of artemether/lumefantrine by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Stay clear of or Use Alternate Drug. Coadministration with robust CYP3A4 inducers may lead to reduced serum concentrations and loss of antimalarial efficacy
pentobarbital will reduce the extent or result of lonafarnib by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Lonafarnib is a delicate CYP3A4 substrate. Coadministration with robust or moderate CYP3A4 inducers is contraindicated.
pentobarbital will minimize the level or result of almotriptan by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check.
pentobarbital will minimize the level or result of clozapine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep track of.
CYP3A4 inducers may increase the formation from the neurotoxic/nephrotoxic ifosfamide metabolite, chloroacetaldehyde. Intently observe patients using ifosfamide with CYP3A4 inducers for toxicities and look at dose adjustment.
pentobarbital decreases amounts of panobinostat by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Solid CYP3A4 inducers can lower panobinostat amounts by ~70% and result in treatment failure.
With therapeutic doses of TCAs, barbiturates boost metabolism and decrease blood concentrations of TCAs.
Phenytoin and barbiturate blood stages should be monitored much more usually if supplied concurrently; influence of barbiturates on phenytoin metabolism claimed to get variable; sodium valproate and valproic acid show up to lower barbiturate metabolism; keep an eye on barbiturate blood stages and make acceptable dosage adjustments as necessary
pentobarbital decreases amounts of ponatinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Stay clear of or Use Alternate Drug. Stay away from unless the coadministration outweighs the feasible risk of ponatinib underexposure; observe for signs of decreased efficacy.
Reserve concomitant prescribing of such drugs in individuals for whom other treatment selections are insufficient. Restrict dosages and durations into the minimal expected. Keep track of closely for indications of respiratory melancholy and sedation.
Should the buprenorphine dose is inadequate and the CYP3A4 inducer cannot be minimized or discontinued, changeover the patient more info back to some buprenorphine formulation that permits dose adjustments.
pentobarbital will lower the level or result of fludrocortisone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep track of.
pentobarbital will reduce the extent or outcome of darifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep track of.
Reserve concomitant prescribing of those drugs in individuals for whom other treatment method choices are inadequate. Restrict dosages and durations towards the bare minimum essential. Keep track of intently for signs of respiratory depression and sedation.